Previously, IMPRESS trial found that continuation of gefitinib plus chemotherapy did not show PFS benefit (5.4 versus 5.4 months) than chemotherapy alone in EGFR-mutant patients with advanced NSCLC and progressed from first-line EGFR-TKI.39 Thus, chemotherapy is the current standard of care in this setting with median PFS of 4–5 months and OS of 16–18 months. This evidence concerns the gene EGFR and non-small cell lung carcinoma.